IntroductionProgrammed cell death protein 1 (PD-1) and its ligand, PD-L1, are crucial immune checkpoints that regulate the ...

programmed cell death protein 1 (PD-1) has been regarded as a leading target in cancer treatments. A checkpoint receptor that ...

About PD-1 Inhibitors PD-1 inhibitors work by blocking the PD-1 (programmed death-1) receptor on T cells, preventing cancer cells from evading the immune system and restoring the body’s ability to ...

The keys to the lock are immune checkpoints such as programmed cell-death ligand 1 (PD-L1), and its receptor PD-1; discovering this system earned Nobel Prizes for James Allison, at the University ...

PD-L1 is a cell surface receptor expressed on both tumour and regulatory ... given as a monotherapy or in combination with MSD’s PD-1 inhibitor Keytruda (pembrolizumab), a widely-used treatment ...

The explosion of GLP-1 weight loss drugs is reminiscent of the early days of PD-1 inhibitors, but key market differences ...

and Palobiofarma’s adenosine A2A receptor inhibitor taminadenant (NIR178) in various cancer indications. With six PD-1/PD-L1 inhibitors on the market – and the most recent entrants struggling ...

A new cancer therapy utilising a genetically modified herpes simplex virus type 1 (HSV-1) offers hope for late-stage patients ...

An early pilot trial suggests that combining atezolizumab (tecectriq) with rituximab (Rituxan), gemcitabine (gemzar) and ...

Findings on golidocitinib for patients with non-small cell lung cancer whose disease has progressed on anti-PD-1 therapy will ...

Glucagon-like peptide-1 (GLP-1) receptor agonists are peptide-based therapeutics for treating diabetes and for weight loss.